ImmunoGen, Inc. (IMGN) Financials

IMGN Assets vs Liabilities
DateAssetsLiabilities
Sept. 30, 2023 822.1 million 260.5 million
June 30, 2023 714.3 million 223.5 million
March 31, 2023 288.3 million 166.4 million
Dec. 31, 2022 348.9 million 193.1 million

IMGN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 1.4 million 7.8 million
June 30, 2023 -66.8 million 7.4 million
March 31, 2023 -73.9 million 7.1 million
Dec. 31, 2022 -60.4 million 10.8 million

IMGN Net Income

No data available :(

IMGN Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 605.5 million - 12.2 million
June 30, 2023 572.0 million - 13.3 million
March 31, 2023 201.2 million - 14.3 million
Dec. 31, 2022 275.1 million - 15.2 million

IMGN Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 287.6 million
June 30, 2023 263.4 million
March 31, 2023 258.8 million
Dec. 31, 2022 254.4 million

IMGN Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 1.4 million 47.6 million 37.7 million -
June 30, 2023 78000 50.1 million 36.4 million -
March 31, 2023 209000 51.6 million 40.0 million -
Dec. 31, 2022 248000 58.5 million 23.8 million 18.3 million

IMGN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2023 113.4 million 2.2 million
June 30, 2023 83.2 million 909000
March 31, 2023 49.9 million 626000
Dec. 31, 2022 41.2 million 176000

IMGN

Price: $31.24

52 week price:
3.61
31.25

Earnings Per Share: -0.28 USD

P/E Ratio: -111.54

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 2.7 million

Ebitda: -9.9 million

Market Capitalization: 8.7 billion

Links: